How Anti-Oestrogens Affect Doxorubicin Toxicity in Cancer Cells
Author Information
Author(s): J. Kirk, S. Houlbrook, N.S.A. Stuart, I.J. Stratford, A.L. Harris, J. Carmichael
Primary Institution: ICRF Laboratories, Institute of Molecular Medicine, John Radcliffe Hospital, Oxford
Hypothesis
Can anti-oestrogens like tamoxifen and toremifene enhance the toxicity of doxorubicin in multidrug resistant cancer cell lines?
Conclusion
Anti-oestrogens significantly enhance doxorubicin toxicity in multidrug resistant cell lines but do not affect intrinsically resistant cells.
Supporting Evidence
- Tamoxifen and toremifene enhanced doxorubicin toxicity in P-glycoprotein-positive cell lines.
- Modification of doxorubicin toxicity was observed at clinically achievable concentrations of anti-oestrogens.
- Anti-oestrogens did not affect doxorubicin toxicity in P-glycoprotein-negative cells.
Takeaway
This study found that certain cancer drugs can help make another cancer drug work better in some resistant cancer cells.
Methodology
The study compared the effects of anti-oestrogens on doxorubicin toxicity using various human cancer cell lines.
Limitations
The study primarily focused on specific cell lines and may not represent all cancer types.
Statistical Information
P-Value
p<0.001
Statistical Significance
p<0.001
Want to read the original?
Access the complete publication on the publisher's website